'Huge Leap Forward' for Low-Risk Prostrate Cancer With VPT Therapy

• comments
• 
• 

The researcher has released a new finding that can treat prostate cancer that integrates with the laser and can be truly effective. They've conducted the test across Europe and the findings will amaze the patient.

Four hundred fifteen men receive the test and almost half are completely free from cancer. While 13.5 percent of the control group want to make it top unlike the current result with combative treatment that can weaken the patient and affect the urine.

According to Med Scape , every man in the experimental arm accept padeloperfin VPT with the dose of 4mg/kg taking place within a 10 minute for a meantime. This will locate to the infected prostate and the laser light will be activated for 22 min and 15 sec.

When the patient receives a successful treatment, some of them will free from any side effects after 2 years. According to Engadget , scientists of Weizmann Institute of Science in Israel developed the "vascular targeted photodynamic therapy" together with the private company STEBA Biotech.

Scientist recommends patient with bilateral disease must check and get a second course of therapy for the contralateral tissue.The first biopsy will be conducted at 12 months when men would go for a second medication with a possible tissue might have positive cancer.

Mark Emberton, lead researcher of University College London Hospital said that the treatment was indeed a big advancement for prostate cancer. Upon their investigation, they have found out 6% of patients will remove their prostate necessarily and 30% of them is under for examination.

But their research must be upgraded because the treatment would be better only for low-risk patients to lower the chance of progressing cancer. Meanwhile, they are looking for a possibility that VTP can manipulate for medium-to-high-risk cases while waiting for good results.

As of now, UK patient has claimed that the system was working fine who is diagnosed with early prostate cancer. However, researcher clarifies that VTP treatment only helps patient with the low-risk prostate patient but they were looking forward to giving a medication to major cases.